Post Award

News

Why opening up clinical trials data is good for pharmaceutical companies

Published November 13, 2013 by OSP


Lessons from past trials about the heterogeneity of treatment effects not only will streamline drug development but also may enhance a drug's value in the marketplace. Identification of a population with high unmet need in which a new treatment may be more cost-effective than other available treatments can aid sponsors during reimbursement negotiations.

Read More>